| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Trevi Therapeutics, Inc. | Chief Scientific Officer | Common Stock | 220K | $653K | $2.96 | Aug 19, 2024 | Direct |
| Trevi Therapeutics, Inc. | Chief Scientific Officer | Stock Option (right to buy) | 0 | Aug 19, 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| TRVI | Trevi Therapeutics, Inc. | Aug 19, 2024 | 3 | -$25.3K | 4 | Aug 21, 2024 | Chief Scientific Officer |
| TRVI | Trevi Therapeutics, Inc. | Aug 14, 2024 | 9 | -$42.2K | 4 | Aug 16, 2024 | Chief Scientific Officer |
| TRVI | Trevi Therapeutics, Inc. | May 29, 2024 | 3 | -$6.12K | 4 | May 31, 2024 | Chief Scientific Officer |
| TRVI | Trevi Therapeutics, Inc. | Feb 15, 2024 | 1 | $0 | 4 | Feb 16, 2024 | Chief Scientific Officer |
| TRVI | Trevi Therapeutics, Inc. | Feb 16, 2023 | 1 | $0 | 4 | Feb 16, 2023 | Chief Scientific Officer |
| TRVI | Trevi Therapeutics, Inc. | Sep 19, 2022 | 1 | $0 | 4 | Sep 19, 2022 | Chief Medical Officer |
| TRVI | Trevi Therapeutics, Inc. | Jun 29, 2022 | 1 | $0 | 4 | Jul 1, 2022 | Chief Medical Officer |
| TRVI | Trevi Therapeutics, Inc. | Feb 11, 2022 | 1 | $0 | 4/A | Jul 1, 2022 | Chief Medical Officer |